Happy medium: considerations in scaling cell culture media strategies
August 16, 2023
While attractive from an initial cost perspective, performing early development in a cell culture substrate that does not match a therapy’s final manufacturing platform can have critical implications on development timelines. In this podcast, Charlotte Barker, Editor, BioInsights, speaks to Dalip Sethi, Director of Scientific Affairs, Terumo BCT, about best practices for scaling up cell culture substrate.
Cell culture media is a big consideration for therapy developers— does Terumo Blood and Cell Technologies (BCT) have a media offering?
What are some of the main considerations in choosing a cell culture medium?
What are the media-related considerations when you are using a closed automated bioreactor system—including the in-process analytical components?
Where do equipment and consumables factor into this conversation?
That’s very interesting to note… Not the ‘first line’ issues that you mentioned earlier, but certainly something that can affect therapy development timelines. What does Terumo BCT see as a mitigation strategy?
How would you say your customers’ needs are changing as the industry matures?